Magdalena TyrpienCo-Founder and CEO at Nionyx BioPresenter
Profile
Magdalena Tyrpien is the Co-Founder and CEO of Nionyx Bio, a New York-based biotech developing next-generation AAV gene therapies for kidney disease. Previously Chief Business Officer at Forge Biologics, she led its $620 M acquisition by Ajinomoto. Magdalena has built and financed multiple gene therapy companies and now leads Nionyx in advancing safe, one-time treatments for renal disorders.
Agenda Sessions
Startup Spotlight pitch competition
, 15:00View Session
